MedTrace Logo

A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms

NCT03669640 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 131

Last updated 2024-08-12

Study results available
· View outcomes & findings →

Summary

This study investigates the effects of RO6889450 on the negative symptoms associated with schizophrenia and schizoaffective disorder.

Conditions

  • Schizophrenia, Schizoaffective Disorder

Interventions

DRUG

RO6889450

Participants will receive a once-daily, oral dose of RO6889450 for 12 weeks.

DRUG

Placebo

Participants will receive a once-daily, oral dose of placebo matched to RO6889450 for 12 weeks.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-04
Primary Completion
2023-03-12
Completion
2023-03-12
FDA Drug
Yes

Countries

  • United States
  • Japan
  • Spain
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03669640 on ClinicalTrials.gov